Answers are grounded in this paper and cite their sources.
Objective: To assess the efficacy and safety of the CEREGLIDE 71 Intermediate Catheter in a real-world clinical setting. Methods: This was a retrospective, single-center, post-market observational study. All consecutive patients with acute ischemic stroke (AIS) who underwent mechanical thrombectomy (MT) with CEREGLIDE 71 between October 2024 and September 2025 were included. The primary outcome was the rate of successful recanalization (final modified Thrombolysis in Cerebral Infarction [mTICI] ≥2b). Secondary efficacy outcomes included complete revascularization (final mTICI ≥2c), first-pass mTICI ≥2c, and first-pass mTICI ≥2b. Safety and clinical outcomes included device-related adverse events, such as vessel dissection, perforation, or catheter breakage, and good functional outcome at 90 days (modified Rankin Scale [mRS] score ≤2). The subgroup of patients treated with a direct aspiration first-pass technique (ADAPT) as the first-line approach was also analyzed. Results: A total of 75 patients underwent MT with CEREGLIDE 71 between October 2024 and September 2025. First-line technique was ADAPT in 76% of procedures (57/75) and combined technique in 24% (18/75). Successful revascularization (mTICI ≥2b) was achieved in 88.0% of patients (66/75). Good functional outcome (90-day mRS ≤2) was observed in 57.3% of patients (43/75). No device-related adverse events were recorded. In the ADAPT subgroup, the SNAKE technique allowed the catheter to reach the clot in 93.0% of cases (53/57). Conclusions: CEREGLIDE 71 appeared to be a feasible and effective option for MT in patients with AIS due to large vessel occlusion (LVO), reaching the occlusion site with the SNAKE technique alone in most procedures.
No takes yet. Share an insight, caveat, or question.
Trombatore et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: